Additionally, peripheral blood leukocyte ACSL4, CRLS1, CTP1A, SIGIRR, SSBP1, and ZNF622 genes containing DMPs might be used as serum biomarkers to stratify NAFLD patients into groups with simple hepatic steatosis and NASH (34). This evidence concerns the gene CRLS1 and metabolic dysfunction-associated steatohepatitis.